Clinical Trial

Effect of Cardiovascular Autonomic Neuropathy on AKI and Outcomes in Isolated CABG Surgery

Study acronym: CAN-AKI-CABG
Completed
View on ClinicalTrials.gov →
Summary
This study aims to investigate the effects of Cardiovascular Autonomic Neuropathy (CAN) on Acute Kidney Injury (AKI) and clinical outcomes in patients undergoing isolated Coronary Artery Bypass Graft (CABG) surgery requiring extracorporeal circulation(ECC). Preoperative data including demographics, comorbidities, kidney function tests, hemodynamic parameters, and baseline regional cerebral oxygen saturation (rSO2) will be recorded. Intraoperative data will include hemodynamics, urine output, blood gases, cardiopulmonary bypass and aortic cross-clamp times, cardioplegia details, number of coronary anastomoses, and rSO2 changes at defined time points. Postoperatively, kidney function, neurological status, mechanical ventilation duration, inotropic drug use, transfusion requirements, complications, ICU and hospital length of stay, and mortality will be evaluated. Acute Kidney Injury will be classified according to KDIGO criteria. The primary objective is to analyze the effect of CAN on AKI. Secondary objectives include assessing the impact of CAN on other clinical outcomes and exploring the relationship between CAN and intraoperative cerebral oxygen changes. This study has been approved by the Acıbadem University and Acıbadem Healthcare Institutions Medical Research Ethics Committee (ATADEK) and will be conducted following ethical principles and good clinical practice.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-25.
Status change: Active, Not Recruiting → Completed 2026-04-09
Trial Details
NCT Number NCT07254468
Lead Sponsor Akdeniz University
Conditions Acute Kidney Injury (AKI), Coronary Artery Bypass Graft (CABG), Cardiovascular Autonomic Neuropathy (CAN), Postoperative Outcomes
Enrollment 912 participants
Start Date 2021-11-04
Primary Completion 2025-01-10 (estimated)
Study Completion 2025-03-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-13